Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Italy
Johannes Wesling Clinic, Minden, Germany
St. István and St. László Hospital, Semmelweis University 3rd Department of Internal Medicine, Budapest, Hungary
Royal Brisbane & Women’s Hospital, Brisbane, QLD, Australia
Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy
Guy’s and St. Thomas’ NHS Foundation Trust, London, UK
University of Naples Federico II, Italy
ZNA Stuivenberg, Antwerp, Belgium
Department of Hematology and Oncology, University of Yamanshi, Chuo-shi, Japan
Hematology Department, Hospital del Mar, Barcelona, Spain
Department of Clinical Hematology and Diagnostics, Osaka City University Graduate School of Medicine, Japan
Hospital Jose Maria Ramos Mejia, Buenos Aires, Argentina
Saint Agnes Cancer Institute, Baltimore, MD, USA
Department of Hematology, University of Pavia, Italy
Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
Medical Department, Division of Hematology, Oncology, and Tumor Immunology, Charité Universitätsmedizin Berlin, Germany
Department of Hematology/Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Novartis Pharma S.A.S, Rueil Malmaison, France
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Centre d’Investigations Cliniques (INSERM CIC 1427), Hôpital Saint-Louis and Université Paris Diderot, Paris, France
Vol. 101 No. 7 (2016): July, 2016